Press Releases

Rain Therapeutics Announces Presentations on Tarloxotinib at the 30th EORTC-NCI-AACR Symposium

November 6, 2018

FREMONT, Calif., November 6, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data from ongoing studies of Rain’s lead candidate, tarloxotinib, at the 30th annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held November 13-16, 2018 in Dublin, Ireland. Rain collaborators at the University of Auckland and the University of Colorado, Denver will present three posters detailing the efficacy of tarloxotinib in preclinical models.

Details on the presentations are as follows:

Presentation Title: Anti-tumor activity of tarloxotinib, a hypoxia-activated EGFR/HER2 TKI, in HER2 driven cell lines
Presenter: Adriana Estrada-Bernal, Ph.D., University of Colorado, Denver
Date: November 13, 2018
Poster Viewing Time: 12:00 p.m. – 6:30 p.m. GMT

Presentation Title: The hypoxia-activated EGFR/HER2 inhibitor Tarloxotinib is activated by the plasma membrane reductase STEAP4
Presenter: Shevan Silva, Ph.D., University of Auckland
Date: November 16, 2018
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Presentation Title: Targeting tumour hypoxia with tarloxotinib improves the therapeutic efficacy of checkpoint blockade
Presenter: Regan Zhe Fu, MSc, University of Auckland
Date: November 16, 2018
Poster Viewing Time: 10:00 a.m. – 2:00 p.m. GMT

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain Therapeutics website after the presentations conclude.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.
The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

About the Doebele Laboratory, University of Colorado, Denver
The Doebele laboratory at the University of Colorado Anschutz Medical Campus focuses on  generating unique patient-derived cancer models, including human cancer cell lines, to study specific oncogene-driven cancers. The lab has successfully defined intrinsic and acquired resistance mechanisms for ALK and ROS1-driven cancers and was the first to identify NTRK1 gene fusions in lung cancer, generating the pre-clinical data that led to the development of TRK inhibitors for lung and other cancers harboring NTRK gene fusions. More recently, the lab has turned to tackling the clinical problem of treating EGFR exon 20 and HER2 exon 20 mutations as well as other HER-family receptor tyrosine kinase-driven cancers. Ultimately, the lab’s goal is to advance personalized medicine through the identification, analysis, and rational targeting of driver oncogenes in cancer in order to improve the clinical outcomes of patients.

Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Lori Kunkel, M.D. Joins the Rain Therapeutics Scientific Advisory Board (SAB)

October 1, 2018

FREMONT, Calif. – October 1, 2018 – Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, announces the addition of Lori Kunkel, M.D., to its scientific advisory board. Dr. Kunkel is a clinical drug development specialist and strategic advisor to targeted and immuno-oncology biotechnology companies with over twenty years of experience in the oncology space.

“We are excited and privileged to have Dr. Kunkel’s help as part of our scientific advisory board,” said Avanish Vellanki, chief executive officer of Rain Therapeutics. “Dr. Kunkel’s decades of experience in clinical oncology drug development will be invaluable as we continue to advance our lead asset, tarloxotinib, and expand our pipeline with additional targeted therapies.”

Dr. Kunkel currently serves on the board of directors of Loxo Oncology, Inc., Curis, Inc., Maverick Therapeutics, Inc.,and Tocagen, Inc. Previously she has served as acting chief medical officer of Loxo Oncology, Inc., chief medical officer of Pharmacyclics, LLC, and Proteolix, Inc. and vice president of clinical development at Xencor, Inc. Earlier in her career she was a clinical scientist at Genentech, where she worked on the development of RITUXAN ®.

“Dr. Kunkel’s approach to drug development is very similar to ours, and Rain will undoubtedly benefit from her perspectives across the various initiatives ongoing at the Company,” said Robert Doebele, M.D., Ph.D., Rain’s co-founder and chairperson of the scientific advisory board.

Prior to her career in biotechnology, Dr. Kunkel spent a decade in academic medicine as a faculty member at the Bone Marrow Transplant Unit in the Division of Hematology/Oncology at University of California, Los Angeles. She received her medical degree from University of Southern California and her bachelor’s degree in biology from University of California, San Diego. She is board certified in internal medicine and has held board certifications in hematology and oncology.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent HER inhibitor in development as a treatment for non-small cell lung cancer patients with Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

Media Contact

Cait Williamson, Ph.D.
LifeSci Public Relations
+1.646.751.4366
cait@lifescipublicrelations.com


Download

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at Two Upcoming Conferences

August 22, 2018

FREMONT, Calif., August 22, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain’s lead candidate, tarloxotinib, at the New Zealand Society for Oncology Conference being held August 24-25, 2018 and the Queenstown Molecular Biology Meeting being held August 27-29, 2018, both in Queenstown, NZ. The poster presentations describe the plasma membrane reductase responsible for the activation of tarloxotinib exclusively in hypoxic environments. This unique characteristic increases the specificity of tarloxotinib for cancer cells, making it an ideal candidate for the treatment of EGFR Exon 20 mutation-driven non-small cell lung cancer.

Details on the presentations by the University of Auckland’s Translational Therapeutics team are as follows:

New Zealand Society for Oncology Conference
Poster Presentation Title
: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: Shevan Silva
Date/Time: August 24, 2018 at 4:45 p.m. NZST
Location: Queenstown Memorial Centre

Queenstown Molecular Biology Meeting
Poster Presentation Title
: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: 
Shevan Silva
Date/Time: August 28, 2018 at 4:30 p.m. NZST
Location: Rydges Hotel, Queenstown

Additional details can be found on the New Zealand Society for Oncology website and the Queenstown Molecular Biology Meeting website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain website after the presentations conclude.

 

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

 

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

 

Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Rain Therapeutics Announces Collaborator Presentations on Tarloxotinib at the 5th International Conference on Tumor Microenvironment and Cellular Stress

June 5, 2018

FREMONT, Calif., June 5, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain’s lead candidate, Tarloxotinib, at the 5th International Conference on Tumor Microenvironment and Cellular Stress: Signalling Metabolism, Imaging and Therapeutic Targets being held June 8-13, 2018 in Chania, Crete, Greece. An oral presentation will detail the discovery of the plasma membrane reductase responsible for activating Tarloxotinib at the site of the tumor, and a poster presentation will discuss data collected in studies of Tarloxotinib that reveal favorable in vivo properties to be a treatment strategy for  patients with EGFR / HER Exon 20 insertion mutations in non-small cell lung cancer (NSCLC).

Details on the presentations by the University of Auckland’s Translational Therapeutics team are as follows:

Poster Presentation Title: Hypoxia tumour targeting with Tarloxotinib to improve clinical outcomes for patients with EGFR-dependent malignancies
Presenter: Victoria Jackson-Patel
Date/Time: June 9, 2018 at 10:30 am EEST

Oral Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Session: Session XI: Clinical-Therapeutic implications
Presenter: Adam V Patterson, Ph.D.
Date/Time: June 12, 2018 at 1:30 pm EEST

Additional details can be found on the conference website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain website after the presentations conclude.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

About the Translational Therapeutics Team, University of Auckland.

The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.

Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com


Download

Rain Therapeutics Closes $18 Million Series A Financing

May 21, 2018

FREMONT, Calif., May 21, 2018 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced the closing of a tranched Series A financing of $18.4 million. The financing was led by San Francisco-based, Biotechnology Value Fund (BVF) and followed by Perceptive Advisors, Auckland UniServices Limited’s Inventors Fund and other private investors. BVF’s Gorjan Hrustanovic, Ph.D., will join the Rain Board of Directors in conjunction with the financing. The Series A round follows a $1 million convertible note financing completed in late-2017.

Rain plans to use the proceeds to advance the clinical development of its lead program, Tarloxotinib (Tarlox), in patients with EGFR and ErbB Exon 20 insertion mutations in non-small cell lung cancer (NSCLC). The company intends to commence a Phase 2 study in patients with EGFR and ErbB Exon 20 insertion mutations in NSCLC in the first half of 2019.

“With the proceeds from recent financings we can complete a Phase 2, proof-of-concept study and continue to advance Tarloxotinib,” said Avanish Vellanki, Rain’s co-founder and chief executive officer. “Our goal is to provide Exon 20 patients with a novel treatment option that results in strong anti-tumor responses while avoiding the debilitating, dose-limiting EGFR toxicities in the gut and skin that are associated with conventional small molecule inhibitors.”

“Targeting wildtype EGFR, or wildtype EGFR-like tumors has always been very challenging with conventional small molecule inhibitors because of the abundance of EGFR in healthy tissues,” said Robert Doebele, M.D., Ph.D., co-founder of Rain Therapeutics, and associate professor of medicine and director of the Thoracic Oncology Research Initiative at the University of Colorado.  “Patients with Exon 20 lung cancer show an addiction to EGFR, however the resemblance of EGFR Exon 20 to EGFR wildtype suggests most conventional strategies will be limited by toxicity. With its novel mechanism of action, Tarlox has the potential to address this inherent, unmet challenge in Exon 20 patients.”

Rain has worldwide development and commercialization rights for Tarlox through an exclusive license to technology developed at the University of Auckland.

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc., has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com

Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.212.915.2575
cait@lifescipublicrelations.com


Download